SNN logo

SMITH & NEPHEW PLC -SPON ADR

SNNNYSE
US Equity
$471.05β–² $24.12 (+5.12%)
Simulated price
πŸ””
Track SNN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 5.1%
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$195.67B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+6.0%
Slowing
πŸ“ŠGross Margin
68.2%
High
πŸ’΅FCF Margin
13.6%
Healthy
βš–οΈP/S Ratio
1.8x
Cheap
Otter Score
76
Good
No chart data available for SNN.

Trading Snapshot

Day Range
$465.15 – $479.68
52-Week Range
$991.00 – $1,426.50
Volume
$2.35B
Avg Volume
$2.53B
Shares Outstanding
840.5M
Next Earnings
Nov 25, 2026

Fundamentals Snapshot

Annual Revenue
$6.16B
Last Q Revenue
$3.10B
P/E Ratio
17.6
P/S Ratio
1.8x
EPS (TTM)
$0.74
Dividend Yield
2.98%
Dilution (1yr)
βˆ’0.8%

Why Investors Own SNN

  • βœ“High-growth profile β€” revenue up +13.3% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 72% gross margin and 16% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SNN logo

SMITH & NEPHEW PLC -SPON ADR

SNN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$6.2Bβ–² +6.1% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
68.3%β–Ό βˆ’2.8% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$794Mβ–² +20.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$852Mβ–² +40.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
436.5Mβ–Ό βˆ’0.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$2.8Bβ–Ό βˆ’$68M YoY
StockOtter Β· stockotter.space

About SMITH & NEPHEW PLC -SPON ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
76/100

Analyst Price Target

β“˜
Average Target
$591.48
β–² +25.6% Upside
High Target$655.66
Low Target$494.56
Based on 21 analysts

Latest News & Updates